The patent application encompasses formulations and compounds that can be instrumental in the development of efficient intradermal vaccines.
Alexander Andrianov, Apogee’s vice president of R&D, said: “The new patent application is filed on the basis of findings obtained in our in vivo proof-of-concept studies. The patent application is designed to protect formulations and compounds capable of improving both the device production technology and the efficacy of intradermal vaccines.”